Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum

We tested the hypothesis that candesartan improves outcomes in heart failure (HF) with mid‐range ejection fraction [HFmrEF; ejection fraction (EF) 40–49%].

[1]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[2]  Karl Swedberg,et al.  Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.

[3]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[4]  Akshay S. Desai,et al.  Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. , 2016, European heart journal.

[5]  L. Lund,et al.  Microvascular endothelial dysfunction in heart failure with preserved ejection fraction , 2016, Heart.

[6]  Akshay S. Desai,et al.  Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. , 2016, Circulation. Heart failure.

[7]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[8]  L. Lund,et al.  Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. , 2017, JACC. Heart failure.

[9]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[10]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[11]  T. Shiroto,et al.  Characterization of heart failure patients with mid‐range left ventricular ejection fraction—a report from the CHART‐2 Study , 2017, European journal of heart failure.

[12]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[13]  Gianluigi Savarese,et al.  A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction , 2017, European journal of heart failure.

[14]  P. Ponikowski,et al.  What have we learned about heart failure with mid‐range ejection fraction one year after its introduction? , 2017, European journal of heart failure.

[15]  D. Mann,et al.  Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid‐range ejection fraction , 2017, European journal of heart failure.

[16]  Robert N. Doughty,et al.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.

[17]  M. Pfisterer,et al.  Heart failure with mid‐range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME‐CHF) , 2017, European journal of heart failure.

[18]  Roberto Ferrari,et al.  Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[19]  D. Mele,et al.  Left ventricular ejection fraction and heart failure: an indissoluble marriage? , 2018, European journal of heart failure.

[20]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[21]  C. Lam,et al.  The middle child in heart failure: heart failure with mid‐range ejection fraction (40–50%) , 2014, European journal of heart failure.

[22]  B. Borlaug,et al.  Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure Spectrum , 2011, Circulation.

[23]  Dike B. Ojji,et al.  Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. , 2015, JACC. Cardiovascular imaging.

[24]  L. Lund,et al.  Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction , 2017, European journal of heart failure.

[25]  L. Lund,et al.  Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study , 2017, Circulation. Heart failure.

[26]  M. de Antonio,et al.  Recovered heart failure with reduced ejection fraction and outcomes: a prospective study , 2017, European journal of heart failure.

[27]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.